Zhuhai Rundu Pharmaceutical Passes US FDA On-Site Manufacturing Practice Inspection

MT Newswires Live06-27

Zhuhai Rundu Pharmaceutical (SHE:002923) passed an on-site inspection from the US Food and Drug Administration related to nine active pharmaceutical ingredients, according to a Friday filing with the Shenzhen bourse.

The inspection is related to current good manufacturing practices involving the production of candesartan cilexetil, olmesartan medoxomil, valsartan, irbesartan, valsartan sodium, sacubitril sodium, sacubitril-valsartan sodium, voriconazole, and hydroxychloroquine sulfate.

The FDA inspection covered quality, production, equipment, laboratory control, and material management systems, the filing said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2546790442?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-27 16:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546790442","market":"sh","top_or_hot":-1,"title":"Zhuhai Rundu Pharmaceutical Passes US FDA On-Site Manufacturing Practice Inspection","media":"MT Newswires Live","content":"<html><body><p> Zhuhai Rundu Pharmaceutical (SHE:002923) passed an on-site inspection from the US Food and Drug Administration related to nine active pharmaceutical ingredients, according to a Friday filing with the Shenzhen bourse.</p><p>The inspection is related to current good manufacturing practices involving the production of candesartan cilexetil, olmesartan medoxomil, valsartan, irbesartan, valsartan sodium, sacubitril sodium, sacubitril-valsartan sodium, voriconazole, and hydroxychloroquine sulfate.</p><p>The FDA inspection covered quality, production, equipment, laboratory control, and material management systems, the filing said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhuhai Rundu Pharmaceutical Passes US FDA On-Site Manufacturing Practice Inspection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhuhai Rundu Pharmaceutical Passes US FDA On-Site Manufacturing Practice Inspection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-27 16:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Zhuhai Rundu Pharmaceutical (SHE:002923) passed an on-site inspection from the US Food and Drug Administration related to nine active pharmaceutical ingredients, according to a Friday filing with the Shenzhen bourse.</p><p>The inspection is related to current good manufacturing practices involving the production of candesartan cilexetil, olmesartan medoxomil, valsartan, irbesartan, valsartan sodium, sacubitril sodium, sacubitril-valsartan sodium, voriconazole, and hydroxychloroquine sulfate.</p><p>The FDA inspection covered quality, production, equipment, laboratory control, and material management systems, the filing said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"002923","symbol_name":"润都股份","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2546790442","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546790442","pubTimestamp":1751013205,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Zhuhai Rundu Pharmaceutical  passed an on-site inspection from the US Food and Drug Administration related to nine active pharmaceutical ingredients, according to a Friday filing with the Shenzhen bourse.The inspection is related to current good manufacturing practices involving the production of candesartan cilexetil, olmesartan medoxomil, valsartan, irbesartan, valsartan sodium, sacubitril sodium, sacubitril-valsartan sodium, voriconazole, and hydroxychloroquine sulfate.The FDA inspection covered quality, production, equipment, laboratory control, and material management systems, the filing said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"002923":"润都股份","BK0239":"医药制造"},"translate_title":"珠海润都制药通过美国FDA现场生产规范检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002923":0.9},"content_text":"Zhuhai Rundu Pharmaceutical (SHE:002923) passed an on-site inspection from the US Food and Drug Administration related to nine active pharmaceutical ingredients, according to a Friday filing with the Shenzhen bourse.The inspection is related to current good manufacturing practices involving the production of candesartan cilexetil, olmesartan medoxomil, valsartan, irbesartan, valsartan sodium, sacubitril sodium, sacubitril-valsartan sodium, voriconazole, and hydroxychloroquine sulfate.The FDA inspection covered quality, production, equipment, laboratory control, and material management systems, the filing said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2546790442","isCrawlerRequest":true}